<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04517110</url>
  </required_header>
  <id_info>
    <org_study_id>OPIATE-2020</org_study_id>
    <nct_id>NCT04517110</nct_id>
  </id_info>
  <brief_title>Perioperative Pregabalin for Reducing Opioid Consumption After Cardiac Surgery</brief_title>
  <acronym>OPIATE</acronym>
  <official_title>Peri-Operative Pregabalin for Reducing opIoid Consumption AfTer Cardiac surgEry: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hamilton Health Sciences Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      OPIATE is a double-blinded randomized controlled trial (RCT) comparing pregabalin in addition&#xD;
      to usual care to usual care alone for reducing post-operative opioid consumption in patients&#xD;
      undergoing on-pump cardiac surgery. Patients will be randomized in a 1:1 ratio to receive&#xD;
      either pregabalin (300 mg pre-operatively + 75 mg post-operatively twice daily until&#xD;
      discharge or 5 days) in addition to usual care or matching placebos in addition to usual&#xD;
      care. The aim of the trial is to show that pregabalin is superior to usual care (i.e. a&#xD;
      superiority trial).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By administering oral pregabalin to patients before and after cardiac surgery for pain&#xD;
      relief, we aim to reduce the amount of opioids they will require for pain relief and reduce&#xD;
      opioid-related side effects that they may experience after surgery. Participants will be&#xD;
      randomly assigned to receive either pregabalin in addition to usual care or usual care alone.&#xD;
      Participants in the pregabalin group will receive two 150 mg pregabalin capsules (300 mg&#xD;
      total dose) within 2 hours before surgery and a 75 mg pregabalin capsule twice daily after&#xD;
      surgery until discharge from hospital to a maximum of 5 days after surgery. Participants in&#xD;
      the usual care group will receive two placebo study capsules within 2 hours before surgery&#xD;
      and a placebo capsule twice daily after surgery until discharged from hospital to a maximum&#xD;
      of 5 days after surgery. OPIATE will be the largest clinical trial of pregabalin in cardiac&#xD;
      surgery with results that are expected to set new post-operative pain management guidelines&#xD;
      to encourage the widespread use of pregabalin in cardiac patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2021</start_date>
  <completion_date type="Anticipated">October 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 9, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blinded randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Matching placebo capsules</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative opioid consumption</measure>
    <time_frame>After surgery until discharge from hospital or 5 days, whichever is first.</time_frame>
    <description>Dose of opioids consumed (in morphine equivalents) by participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily opioid consumption</measure>
    <time_frame>Each postoperative day, beginning on postoperative day 1 and ending on the day of discharge from hospital or postoperative day 5, whichever is first.</time_frame>
    <description>Dose of opioids consumed (in morphine equivalents) by participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily postoperative pain</measure>
    <time_frame>Each postoperative day, beginning on postoperative day 1 and ending on the day of discharge from hospital or postoperative day 5, whichever is first.</time_frame>
    <description>Acute postoperative pain assessed by the numeric rating scale (NRS; 0 to 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average postoperative pain</measure>
    <time_frame>Average of scores after surgery until discharge from hospital or 5 days, whichever is first.</time_frame>
    <description>Acute postoperative pain assessed by the numeric rating scale (NRS; 0 to 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative consumption of antiemetic medications</measure>
    <time_frame>After surgery until discharge from hospital or 5 days, whichever is first.</time_frame>
    <description>Dose of gravol or ondansetron consumed by participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily consumption of antiemetic medications</measure>
    <time_frame>Each postoperative day, beginning on postoperative day 1 and ending on the day of discharge from hospital or postoperative day 5, whichever is first.</time_frame>
    <description>Dose of gravol or ondansetron consumed by participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to extubation</measure>
    <time_frame>Within the first 5 days after surgery</time_frame>
    <description>Time from surgery completion until first successful extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mobility</measure>
    <time_frame>Within the first 5 days after surgery</time_frame>
    <description>Proportion of mobility goals met after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delirium</measure>
    <time_frame>Starting the second day after surgery and ending after 5 days or 3 days of negative tests.</time_frame>
    <description>Number of participants meeting the Confusion Assessment Method (CAM) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>Within the first 5 days after surgery</time_frame>
    <description>The first occurrence of death, non-fatal myocardial infarction (MI) or non-fatal stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Within the first 5 days after surgery</time_frame>
    <description>Number of participants experiencing death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>Within the first 5 days after surgery</time_frame>
    <description>Number of participants experiencing myocardial infarction (MI) without death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>Within the first 5 days after surgery</time_frame>
    <description>Number of participants experiencing stroke without death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Opioid Use</condition>
  <arm_group>
    <arm_group_label>Pregabalin + Usual Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg pregabalin taken orally within 2 hours before surgery and 75 mg pregabalin taken orally twice daily after surgery beginning after successful extubation (day after surgery or later) until discharge or 5 days, whichever comes first. Participants will also receive standard pain management.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Usual Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo taken orally within 2 hours before surgery and placebo taken orally twice daily after surgery beginning after successful extubation (day after surgery or later) until discharge or 5 days, whichever comes first. Participants will also receive standard pain management.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 300 mg</intervention_name>
    <description>Pregabalin 300 mg, capsule</description>
    <arm_group_label>Pregabalin + Usual Care</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 75 mg</intervention_name>
    <description>Pregabalin 75 mg twice daily, capsules</description>
    <arm_group_label>Pregabalin + Usual Care</arm_group_label>
    <other_name>Lyrica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 300 mg Placebo</intervention_name>
    <description>Placebo, matching Pregabalin 300 mg capsule</description>
    <arm_group_label>Placebo + Usual Care</arm_group_label>
    <other_name>Placebo Capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 75 mg Placebo</intervention_name>
    <description>Placebo, matching Pregabalin 75 mg capsules</description>
    <arm_group_label>Placebo + Usual Care</arm_group_label>
    <other_name>Placebo Capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Usual Care</description>
    <arm_group_label>Placebo + Usual Care</arm_group_label>
    <arm_group_label>Pregabalin + Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥ 18 years of age&#xD;
&#xD;
          2. Undergoing cardiac surgery with median sternotomy&#xD;
&#xD;
          3. Provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of opioids or cannabis products in the past 30 days&#xD;
&#xD;
          2. Daily use of pregabalin or gabapentin within 7 days of randomization&#xD;
&#xD;
          3. Intravenous drug user&#xD;
&#xD;
          4. Have a hypersensitivity or allergy to pregabalin&#xD;
&#xD;
          5. History of previous cardiac surgery&#xD;
&#xD;
          6. Undergoing minimally invasive surgery&#xD;
&#xD;
          7. Emergency surgery&#xD;
&#xD;
          8. Severe renal impairment (creatinine &gt; 250 μmol/L)&#xD;
&#xD;
          9. Unable to swallow study medications&#xD;
&#xD;
         10. Pregnant or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre Lamy, MD, MHSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Austin Browne, PhD</last_name>
    <phone>19052973479</phone>
    <phone_ext>40582</phone_ext>
    <email>Austin.Browne@phri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andre Lamy, MD, MHSc</last_name>
    <email>lamya@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andre Lamy, MD, MHSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Pesonen A, Suojaranta-Ylinen R, Hammarén E, Kontinen VK, Raivio P, Tarkkila P, Rosenberg PH. Pregabalin has an opioid-sparing effect in elderly patients after cardiac surgery: a randomized placebo-controlled trial. Br J Anaesth. 2011 Jun;106(6):873-81. doi: 10.1093/bja/aer083. Epub 2011 Apr 6.</citation>
    <PMID>21474474</PMID>
  </reference>
  <reference>
    <citation>Joshi SS, Jagadeesh AM. Efficacy of perioperative pregabalin in acute and chronic post-operative pain after off-pump coronary artery bypass surgery: a randomized, double-blind placebo controlled trial. Ann Card Anaesth. 2013 Jul-Sep;16(3):180-5. doi: 10.4103/0971-9784.114239.</citation>
    <PMID>23816671</PMID>
  </reference>
  <reference>
    <citation>Sundar AS, Kodali R, Sulaiman S, Ravullapalli H, Karthekeyan R, Vakamudi M. The effects of preemptive pregabalin on attenuation of stress response to endotracheal intubation and opioid-sparing effect in patients undergoing off-pump coronary artery bypass grafting. Ann Card Anaesth. 2012 Jan-Mar;15(1):18-25. doi: 10.4103/0971-9784.91473.</citation>
    <PMID>22234017</PMID>
  </reference>
  <reference>
    <citation>Ziyaeifard M, Mehrabanian MJ, Faritus SZ, Khazaei Koohpar M, Ferasatkish R, Hosseinnejad H, Mehrabanian M. Premedication with oral pregabalin for the prevention of acute postsurgical pain in coronary artery bypass surgery. Anesth Pain Med. 2015 Jan 17;5(1):e24837. doi: 10.5812/aapm.24837. eCollection 2015 Feb.</citation>
    <PMID>25830118</PMID>
  </reference>
  <reference>
    <citation>Bouzia A, Tassoudis V, Karanikolas M, Vretzakis G, Petsiti A, Tsilimingas N, Arnaoutoglou E. Pregabalin Effect on Acute and Chronic Pain after Cardiac Surgery. Anesthesiol Res Pract. 2017;2017:2753962. doi: 10.1155/2017/2753962. Epub 2017 Apr 30. Erratum in: Anesthesiol Res Pract. 2018 Oct 17;2018:5981895.</citation>
    <PMID>28539936</PMID>
  </reference>
  <reference>
    <citation>Anwar S, Cooper J, Rahman J, Sharma C, Langford R. Prolonged Perioperative Use of Pregabalin and Ketamine to Prevent Persistent Pain after Cardiac Surgery. Anesthesiology. 2019 Jul;131(1):119-131. doi: 10.1097/ALN.0000000000002751.</citation>
    <PMID>31149930</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hamilton Health Sciences Corporation</investigator_affiliation>
    <investigator_full_name>Andre Lamy</investigator_full_name>
    <investigator_title>Cardiac Surgeon</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

